Biopharmaceutical and Vaccine Production Markets (Mammalian Cell Production, Microbial Cell Production Market, Monoclonal Antibody Manufacturing, Other Recombinant Protein Manufacturing, Vaccine Manufacturing, Insulin Manufacturing Market)

Table of Contents

ONE: Executive Summary

Major Kinds of Biopharmaceuticals

Monoclonal Antibodies

Recombinant Proteins

Vaccines

Insulins

Other Biopharm Protein Products

Approved Biopharmaceutical Products

Biosimilars

TWO: Commercial Production

Process Overview

Production Systems

Cell Culture

Microbial Cells

Mammalian Cell Lines

Plant Cell Cultures

Insect Cells

Transgenics

Transgenic Plants

Transgenic Animals

Cell-Free Protein Production

THREE: Forecasts

Total Biopharmaceutical Manufacturing Costs

FOUR: Regulation

FDA-CBER

Allergenics

Blood and Blood Products

Cellular and Gene Therapy Products

Tissue and Tissue Products

Vaccines

EMA

FIVE: Competitive Environment

Originator and Contract Manufacturing

Outsourcing

Types of Contractors Involved in Biomanufacturing

Demand for Biopharmaceutical Manufacturing Increasing

Production Capacity for Biopharmaceutical Manufacturing

Alternative Methods Of Producing Biopharmaceuticals

CMOs Expanding Operations to Manufacture Biologics

Biomanufacturing in Asia

Top Manufacturers

Integrated R&D, Manufacturing Firms

Merger and Acquisition Activity

Licensing and Collaborations

SIX: Patents

Select Mammalian, Yeast, Insect, Plant, and Transgenic Patents

1. coli Patents

SEVEN: Geography

EIGHT: Profiles

Major Contract Manufacturers

Lonza AG

Boehringer Ingelheim GmbH

FUJIFILM Diosynth Biotechnologies

Sandoz

Royal DSM

Rentschler Biotechnologie

Celonic

BIOMEVA GmbH

ProBioGen AG

Baxter BioPharma Solutions/Baxter Bioscience

Major Biologics Firms

Amgen

Genentech/Roche

AbbVie Inc. (Abbott)

Biogen Idec

Regeneron Pharmaceuticals

Alexion Pharmaceuticals

Crucell /Johnson & Johnson

GlaxoSmithKline

Merck & Co. Inc

Novartis

Pfizer

Sanofi Pasteur

Other Contract Manufacturers

AAIPharma

A-Bio Pharma Pte Ltd.

ABL, Inc.

Affinity Life Sciences, Inc.

Ajinomoto Aminoscience, LLC

Alliance Medical Products, Inc.

Alpha Biologics

Biotecnol

Boston Mountain Biotech

Glycobia

Sutro Biopharma

LIST OF EXHIBITS

ONE: Executive Summary

Table 1-1: Indications for Biologic Class (Erythropoietin, Interferon α, Interferon β, Monoclonal Antibody, Colony Stimulating Factors, Glucocerebrosidase), Partial

Table 1-2: FDA-Approved Therapeutic Monoclonal Antibodies

Table 1-3: Vaccine-Preventable Diseases, 2014

Table 1-4: Major Vaccine Manufacturers

Table 1-5: 2014 Biological License Application Approvals

Table 1-6: 2013 Biological License Application Approvals

Table 1-7: 2013 Biological New Drug Application (NDA) and Abbreviated New Drug Application (ANDA) Approvals

TWO: Commercial Production

Table 2-1: Biopharma Manufacturing Process Overview

Table 2-2: Systems for the Production of Biopharmaceuticals

THREE: Forecasts

Table 3-1: Total Biopharmaceutical Manufacturing Market, 2012-2018

Table 3-2: Mammalian Cell Production Market, 2012-2018

Table 3-3: Microbial Cell Production Market, 2012-2018

Table 3-4: Monoclonal Antibody Manufacturing Market, 2012-2018

Table 3-5: Other Recombinant Proteins, Manufacturing Market, 2012-2018

Table 3-6: Vaccine Manufacturing Market, 2012-2018

Table 3-7: Insulin Manufacturing Market, 2012-2018

FIVE: Competitive Environment

Table 5-1: List of Selected Biopharmaceutical Contract Manufacturers

Table 5-2: Selected Top-Selling Biopharmaceuticals, 2013

Table 5-3: Selected Asia Biomanufacturing CMOs

Table 5-4: Top 10 Biopharma Companies Based on 2012 Biopharma Revenues

Table 5-5: Top Manufacturers by Global Biopharmaceutical Manufacturing Capacity

Table 5-6: Top Pharmaceutical Acquisitions in 2013

List of Exhibits

Table 5-7: Top Ten Pharmaceutical Acquisitions in 2012

Table 5-8: Biopharmaceutical Licensing and Collaboartions in 2013

SIX: Patents

Table 6-1: Selected Biopharmaceutical Manufacturing Patents Granted between January 1, 2013 and July 15, 2014 – Mammal

Table 6-2: Selected Biopharmaceutical Manufacturing Patents Granted between January 1, 2013 and July 15, 2014 – Yeast

Table 6-3: Selected Biopharmaceutical Manufacturing Patents Granted between January 1, 2013 and July 15, 2014 – Insect

Table 6-4: Selected Biopharmaceutical Manufacturing Patents Granted between January 1, 2013 and July 15, 2014 – Plant

Table 6-5: Selected Biopharmaceutical Manufacturing Patents Granted between January 1, 2013 and July 15, 2014 – Transgenic

Table 6-6: Selected Biopharmaceutical Manufacturing Patents Granted between January 1, 2013 and July 15, 2014 – E. coli

SEVEN: Geography

Table 7-1: Estimated Biopharmaceutical Manufacturing Capacity by Region,2014, by Revenues